PubMed:16311883
Annnotations
GlyCosmos6-Glycan-Motif-Image
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 129-139 | Glycan_Motif | denotes | hyaluronan | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00017MO |
T2 | 159-161 | Glycan_Motif | denotes | HA | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00017MO |
T3 | 167-178 | Glycan_Motif | denotes | chondroitin | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G43702JT |
T4 | 1052-1062 | Glycan_Motif | denotes | hyaluronan | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00017MO |
T5 | 1064-1066 | Glycan_Motif | denotes | HA | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00017MO |
T6 | 1132-1134 | Glycan_Motif | denotes | HA | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00017MO |
T7 | 1739-1742 | Glycan_Motif | denotes | GM1 | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G48558GR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G46613JI |
T9 | 1917-1919 | Glycan_Motif | denotes | HA | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00017MO |
T10 | 2051-2053 | Glycan_Motif | denotes | HA | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00017MO |
GlyCosmos6-Glycan-Motif-Structure
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 129-139 | https://glytoucan.org/Structures/Glycans/G00017MO | denotes | hyaluronan |
T2 | 167-178 | https://glytoucan.org/Structures/Glycans/G43702JT | denotes | chondroitin |
T3 | 1052-1062 | https://glytoucan.org/Structures/Glycans/G00017MO | denotes | hyaluronan |
T4 | 1739-1742 | https://glytoucan.org/Structures/Glycans/G46613JI | denotes | GM1 |
T5 | 1739-1742 | https://glytoucan.org/Structures/Glycans/G48558GR | denotes | GM1 |
Glycosmos6-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 167-178 | http://www.glycoepitope.jp/epitopes/EP0081 | denotes | chondroitin |
T2 | 1739-1742 | http://www.glycoepitope.jp/epitopes/EP0050 | denotes | GM1 |
Glycosmos6-MAT
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 1159-1163 | http://purl.obolibrary.org/obo/MAT_0000299 | denotes | bone |
T2 | 1167-1184 | http://purl.obolibrary.org/obo/MAT_0000301 | denotes | connective tissue |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T1 | 0-73 | Sentence | denotes | Serum hyaluronidase aberrations in metabolic and morphogenetic disorders. |
TextSentencer_T2 | 74-188 | Sentence | denotes | Hyaluronidases are endo-glycosidases that degrade both hyaluronan (hyaluronic acid) (HA) and chondroitin sulfates. |
TextSentencer_T3 | 189-326 | Sentence | denotes | Deficiency of hyaluronidase activity has been predicted to result in a phenotype similar to that observed in mucopolysaccharidosis (MPS). |
TextSentencer_T4 | 327-566 | Sentence | denotes | In the present study, we surveyed a variety of patients with phenotypes similar to those observed in MPS, but without significant mucopolysacchariduria to determine if some are based on aberrations in serum hyaluronidase (Hyal-1) activity. |
TextSentencer_T5 | 567-704 | Sentence | denotes | The study included patients with well-characterized dysmorphic disorders occurring on genetic basis, as well as those of unkown etiology. |
TextSentencer_T6 | 705-823 | Sentence | denotes | The purpose of the study was to establish how wide spread were abnormalities in levels of circulating Hyal-1 activity. |
TextSentencer_T7 | 824-930 | Sentence | denotes | A simple and sensitive semi-quantitative zymographic procedure was used for the determination of activity. |
TextSentencer_T8 | 931-1135 | Sentence | denotes | Levels of both beta-N-acetylglucosaminidase and beta-glucuronidase whose activities contribute to the total breakdown of hyaluronan (HA) were also measured, as well as the concentration of circulating HA. |
TextSentencer_T9 | 1136-1349 | Sentence | denotes | Among 48 patients with bone or connective tissue abnormalities, low levels of Hyal-1 activity were found in six patients compared to levels in 100 healthy donors (2.0-3.2 units/microL vs 6(+/- 1 SE) units/microL). |
TextSentencer_T10 | 1350-1652 | Sentence | denotes | These six patients exhibited a wide spectrum of clinical abnormalities, in particular shortened extremities: they included three patients with unknown causes of clinical symptoms, one patient with Sanfilippo disease, one of the seven patients with achondroplasia, and one with hypophosphotemic rickets. |
TextSentencer_T11 | 1653-1861 | Sentence | denotes | Normal levels of serum Hyal-1 activities were found in patients with Morquio disease, GM1 gangliosidosis, I cell-disease, 6 of the 7 patients with achondroplasia, Marfan's-syndrome and Ehlers-Danlos syndrome. |
TextSentencer_T12 | 1862-1910 | Sentence | denotes | No patient totally lacked serum Hyal-1 activity. |
TextSentencer_T13 | 1911-1996 | Sentence | denotes | Serum HA concentration was elevated in patients with Sanfilippo A and I-cell disease. |
TextSentencer_T14 | 1997-2132 | Sentence | denotes | Determination of serum and leukocyte Hyal-1 and serum HA may be useful to evaluate patients with metabolic and morphogenetic disorders. |
TextSentencer_T1 | 0-73 | Sentence | denotes | Serum hyaluronidase aberrations in metabolic and morphogenetic disorders. |
TextSentencer_T2 | 74-188 | Sentence | denotes | Hyaluronidases are endo-glycosidases that degrade both hyaluronan (hyaluronic acid) (HA) and chondroitin sulfates. |
TextSentencer_T3 | 189-326 | Sentence | denotes | Deficiency of hyaluronidase activity has been predicted to result in a phenotype similar to that observed in mucopolysaccharidosis (MPS). |
TextSentencer_T4 | 327-566 | Sentence | denotes | In the present study, we surveyed a variety of patients with phenotypes similar to those observed in MPS, but without significant mucopolysacchariduria to determine if some are based on aberrations in serum hyaluronidase (Hyal-1) activity. |
TextSentencer_T5 | 567-704 | Sentence | denotes | The study included patients with well-characterized dysmorphic disorders occurring on genetic basis, as well as those of unkown etiology. |
TextSentencer_T6 | 705-823 | Sentence | denotes | The purpose of the study was to establish how wide spread were abnormalities in levels of circulating Hyal-1 activity. |
TextSentencer_T7 | 824-930 | Sentence | denotes | A simple and sensitive semi-quantitative zymographic procedure was used for the determination of activity. |
TextSentencer_T8 | 931-1135 | Sentence | denotes | Levels of both beta-N-acetylglucosaminidase and beta-glucuronidase whose activities contribute to the total breakdown of hyaluronan (HA) were also measured, as well as the concentration of circulating HA. |
TextSentencer_T9 | 1136-1349 | Sentence | denotes | Among 48 patients with bone or connective tissue abnormalities, low levels of Hyal-1 activity were found in six patients compared to levels in 100 healthy donors (2.0-3.2 units/microL vs 6(+/- 1 SE) units/microL). |
TextSentencer_T10 | 1350-1652 | Sentence | denotes | These six patients exhibited a wide spectrum of clinical abnormalities, in particular shortened extremities: they included three patients with unknown causes of clinical symptoms, one patient with Sanfilippo disease, one of the seven patients with achondroplasia, and one with hypophosphotemic rickets. |
TextSentencer_T11 | 1653-1861 | Sentence | denotes | Normal levels of serum Hyal-1 activities were found in patients with Morquio disease, GM1 gangliosidosis, I cell-disease, 6 of the 7 patients with achondroplasia, Marfan's-syndrome and Ehlers-Danlos syndrome. |
TextSentencer_T12 | 1862-1910 | Sentence | denotes | No patient totally lacked serum Hyal-1 activity. |
TextSentencer_T13 | 1911-1996 | Sentence | denotes | Serum HA concentration was elevated in patients with Sanfilippo A and I-cell disease. |
TextSentencer_T14 | 1997-2132 | Sentence | denotes | Determination of serum and leukocyte Hyal-1 and serum HA may be useful to evaluate patients with metabolic and morphogenetic disorders. |
T1 | 0-73 | Sentence | denotes | Serum hyaluronidase aberrations in metabolic and morphogenetic disorders. |
T2 | 74-188 | Sentence | denotes | Hyaluronidases are endo-glycosidases that degrade both hyaluronan (hyaluronic acid) (HA) and chondroitin sulfates. |
T3 | 189-326 | Sentence | denotes | Deficiency of hyaluronidase activity has been predicted to result in a phenotype similar to that observed in mucopolysaccharidosis (MPS). |
T4 | 327-566 | Sentence | denotes | In the present study, we surveyed a variety of patients with phenotypes similar to those observed in MPS, but without significant mucopolysacchariduria to determine if some are based on aberrations in serum hyaluronidase (Hyal-1) activity. |
T5 | 567-704 | Sentence | denotes | The study included patients with well-characterized dysmorphic disorders occurring on genetic basis, as well as those of unkown etiology. |
T6 | 705-823 | Sentence | denotes | The purpose of the study was to establish how wide spread were abnormalities in levels of circulating Hyal-1 activity. |
T7 | 824-930 | Sentence | denotes | A simple and sensitive semi-quantitative zymographic procedure was used for the determination of activity. |
T8 | 931-1135 | Sentence | denotes | Levels of both beta-N-acetylglucosaminidase and beta-glucuronidase whose activities contribute to the total breakdown of hyaluronan (HA) were also measured, as well as the concentration of circulating HA. |
T9 | 1136-1349 | Sentence | denotes | Among 48 patients with bone or connective tissue abnormalities, low levels of Hyal-1 activity were found in six patients compared to levels in 100 healthy donors (2.0-3.2 units/microL vs 6(+/- 1 SE) units/microL). |
T10 | 1350-1652 | Sentence | denotes | These six patients exhibited a wide spectrum of clinical abnormalities, in particular shortened extremities: they included three patients with unknown causes of clinical symptoms, one patient with Sanfilippo disease, one of the seven patients with achondroplasia, and one with hypophosphotemic rickets. |
T11 | 1653-1861 | Sentence | denotes | Normal levels of serum Hyal-1 activities were found in patients with Morquio disease, GM1 gangliosidosis, I cell-disease, 6 of the 7 patients with achondroplasia, Marfan's-syndrome and Ehlers-Danlos syndrome. |
T12 | 1862-1910 | Sentence | denotes | No patient totally lacked serum Hyal-1 activity. |
T13 | 1911-1996 | Sentence | denotes | Serum HA concentration was elevated in patients with Sanfilippo A and I-cell disease. |
T14 | 1997-2132 | Sentence | denotes | Determination of serum and leukocyte Hyal-1 and serum HA may be useful to evaluate patients with metabolic and morphogenetic disorders. |
PubCasesHPO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
AB1 | 457-478 | HP:0008155 | denotes | mucopolysacchariduria |
AB2 | 1644-1651 | HP:0002748 | denotes | rickets |
PubCasesORDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
AB1 | 1547-1565 | ORDO:581 | denotes | Sanfilippo disease |
AB2 | 1598-1612 | ORDO:15 | denotes | achondroplasia |
AB3 | 1722-1737 | ORDO:582 | denotes | Morquio disease |
AB4 | 1739-1757 | ORDO:354 | denotes | GM1 gangliosidosis |
AB5 | 1759-1773 | ORDO:576 | denotes | I cell-disease |
AB6 | 1800-1814 | ORDO:15 | denotes | achondroplasia |
AB7 | 1981-1995 | ORDO:576 | denotes | I-cell disease |
performance-test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-UBERON-AE-B_T1 | 1178-1184 | http://purl.obolibrary.org/obo/UBERON_0000479 | denotes | tissue |
PD-UBERON-AE-B_T2 | 0-5 | http://purl.obolibrary.org/obo/UBERON_0001977 | denotes | Serum |
PD-UBERON-AE-B_T3 | 528-533 | http://purl.obolibrary.org/obo/UBERON_0001977 | denotes | serum |
PD-UBERON-AE-B_T4 | 1670-1675 | http://purl.obolibrary.org/obo/UBERON_0001977 | denotes | serum |
PD-UBERON-AE-B_T5 | 1888-1893 | http://purl.obolibrary.org/obo/UBERON_0001977 | denotes | serum |
PD-UBERON-AE-B_T6 | 1911-1916 | http://purl.obolibrary.org/obo/UBERON_0001977 | denotes | Serum |
PD-UBERON-AE-B_T7 | 2014-2019 | http://purl.obolibrary.org/obo/UBERON_0001977 | denotes | serum |
PD-UBERON-AE-B_T8 | 2045-2050 | http://purl.obolibrary.org/obo/UBERON_0001977 | denotes | serum |
PD-UBERON-AE-B_T9 | 1167-1184 | http://purl.obolibrary.org/obo/UBERON_0002384 | denotes | connective tissue |
PD-UBERON-AE-B_T10 | 549-553 | http://purl.obolibrary.org/obo/UBERON_3000101 | denotes | Hyal |
PD-UBERON-AE-B_T11 | 807-811 | http://purl.obolibrary.org/obo/UBERON_3000101 | denotes | Hyal |
PD-UBERON-AE-B_T12 | 1214-1218 | http://purl.obolibrary.org/obo/UBERON_3000101 | denotes | Hyal |
PD-UBERON-AE-B_T13 | 1676-1680 | http://purl.obolibrary.org/obo/UBERON_3000101 | denotes | Hyal |
PD-UBERON-AE-B_T14 | 1894-1898 | http://purl.obolibrary.org/obo/UBERON_3000101 | denotes | Hyal |
PD-UBERON-AE-B_T15 | 2034-2038 | http://purl.obolibrary.org/obo/UBERON_3000101 | denotes | Hyal |
DisGeNET
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T0 | 1676-1682 | gene:6677 | denotes | Hyal-1 |
T1 | 1722-1737 | disease:C0026707 | denotes | Morquio disease |
T2 | 1676-1682 | gene:3373 | denotes | Hyal-1 |
T3 | 1722-1737 | disease:C0026707 | denotes | Morquio disease |
T4 | 1676-1682 | gene:6677 | denotes | Hyal-1 |
T5 | 1838-1860 | disease:C0013720 | denotes | Ehlers-Danlos syndrome |
T6 | 1676-1682 | gene:3373 | denotes | Hyal-1 |
T7 | 1838-1860 | disease:C0013720 | denotes | Ehlers-Danlos syndrome |
R1 | T0 | T1 | associated_with | Hyal-1,Morquio disease |
R2 | T2 | T3 | associated_with | Hyal-1,Morquio disease |
R3 | T4 | T5 | associated_with | Hyal-1,Ehlers-Danlos syndrome |
R4 | T6 | T7 | associated_with | Hyal-1,Ehlers-Danlos syndrome |
Anatomy-MAT
Id | Subject | Object | Predicate | Lexical cue | mat_id |
---|---|---|---|---|---|
T1 | 1159-1163 | Body_part | denotes | bone | http://purl.obolibrary.org/obo/MAT_0000299 |
T2 | 1167-1184 | Body_part | denotes | connective tissue | http://purl.obolibrary.org/obo/MAT_0000301 |
HP-phenotype
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 457-478 | Phenotype | denotes | mucopolysacchariduria | HP:0008155 |
T2 | 1644-1651 | Phenotype | denotes | rickets | HP:0002748 |
mondo_disease
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 298-319 | Disease | denotes | mucopolysaccharidosis | http://purl.obolibrary.org/obo/MONDO_0019249 |
T2 | 321-324 | Disease | denotes | MPS | http://purl.obolibrary.org/obo/MONDO_0019249 |
T3 | 428-431 | Disease | denotes | MPS | http://purl.obolibrary.org/obo/MONDO_0019249 |
T4 | 1547-1565 | Disease | denotes | Sanfilippo disease | http://purl.obolibrary.org/obo/MONDO_0018937 |
T5 | 1598-1612 | Disease | denotes | achondroplasia | http://purl.obolibrary.org/obo/MONDO_0007037 |
T6 | 1644-1651 | Disease | denotes | rickets | http://purl.obolibrary.org/obo/MONDO_0005520 |
T7 | 1722-1737 | Disease | denotes | Morquio disease | http://purl.obolibrary.org/obo/MONDO_0018938 |
T8 | 1739-1757 | Disease | denotes | GM1 gangliosidosis | http://purl.obolibrary.org/obo/MONDO_0018149 |
T9 | 1759-1773 | Disease | denotes | I cell-disease | http://purl.obolibrary.org/obo/MONDO_0009650 |
T10 | 1800-1814 | Disease | denotes | achondroplasia | http://purl.obolibrary.org/obo/MONDO_0007037 |
T11 | 1816-1833 | Disease | denotes | Marfan's-syndrome | http://purl.obolibrary.org/obo/MONDO_0007947 |
T12 | 1838-1860 | Disease | denotes | Ehlers-Danlos syndrome | http://purl.obolibrary.org/obo/MONDO_0020066 |
T13 | 1964-1976 | Disease | denotes | Sanfilippo A | http://purl.obolibrary.org/obo/MONDO_0009655 |
T14 | 1981-1995 | Disease | denotes | I-cell disease | http://purl.obolibrary.org/obo/MONDO_0009650 |
Glycan-GlyCosmos
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 167-178 | Glycan | denotes | chondroitin | https://api.glycosmos.org/wurcs2image/latest/png/binary/G43702JT |
T2 | 1739-1742 | Glycan | denotes | GM1 | https://api.glycosmos.org/wurcs2image/latest/png/binary/G48558GR |
GlyCosmos-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue | glycoepitope_id |
---|---|---|---|---|---|
T1 | 167-178 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | chondroitin | http://www.glycoepitope.jp/epitopes/EP0081 |
T2 | 1739-1742 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | GM1 | http://www.glycoepitope.jp/epitopes/EP0050 |
GlyCosmos15-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 457-478 | Phenotype | denotes | mucopolysacchariduria | HP:0008155 |
T2 | 1644-1651 | Phenotype | denotes | rickets | HP:0002748 |
GlyCosmos15-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 298-319 | Disease | denotes | mucopolysaccharidosis | http://purl.obolibrary.org/obo/MONDO_0019249 |
T2 | 321-324 | Disease | denotes | MPS | http://purl.obolibrary.org/obo/MONDO_0019249 |
T3 | 428-431 | Disease | denotes | MPS | http://purl.obolibrary.org/obo/MONDO_0019249 |
T4 | 1547-1565 | Disease | denotes | Sanfilippo disease | http://purl.obolibrary.org/obo/MONDO_0018937 |
T5 | 1598-1612 | Disease | denotes | achondroplasia | http://purl.obolibrary.org/obo/MONDO_0007037 |
T6 | 1644-1651 | Disease | denotes | rickets | http://purl.obolibrary.org/obo/MONDO_0005520 |
T7 | 1722-1737 | Disease | denotes | Morquio disease | http://purl.obolibrary.org/obo/MONDO_0018938 |
T8 | 1739-1757 | Disease | denotes | GM1 gangliosidosis | http://purl.obolibrary.org/obo/MONDO_0018149 |
T9 | 1759-1773 | Disease | denotes | I cell-disease | http://purl.obolibrary.org/obo/MONDO_0009650 |
T10 | 1800-1814 | Disease | denotes | achondroplasia | http://purl.obolibrary.org/obo/MONDO_0007037 |
T11 | 1816-1833 | Disease | denotes | Marfan's-syndrome | http://purl.obolibrary.org/obo/MONDO_0007947 |
T12 | 1838-1860 | Disease | denotes | Ehlers-Danlos syndrome | http://purl.obolibrary.org/obo/MONDO_0020066 |
T13 | 1964-1976 | Disease | denotes | Sanfilippo A | http://purl.obolibrary.org/obo/MONDO_0009655 |
T14 | 1981-1995 | Disease | denotes | I-cell disease | http://purl.obolibrary.org/obo/MONDO_0009650 |
GlyCosmos15-NCBITAXON
Id | Subject | Object | Predicate | Lexical cue | db_id |
---|---|---|---|---|---|
T1 | 1534-1541 | OrganismTaxon | denotes | patient | 9606 |
T2 | 1865-1872 | OrganismTaxon | denotes | patient | 9606 |
GlyCosmos15-CL
Id | Subject | Object | Predicate | Lexical cue | cl_id |
---|---|---|---|---|---|
T1 | 2024-2033 | Cell | denotes | leukocyte | http://purl.obolibrary.org/obo/CL:0000738 |
GlyCosmos15-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 1159-1163 | Body_part | denotes | bone | http://purl.obolibrary.org/obo/UBERON_0001474|http://purl.obolibrary.org/obo/UBERON_0002481 |
T3 | 1167-1184 | Body_part | denotes | connective tissue | http://purl.obolibrary.org/obo/UBERON_0002384 |
T4 | 1446-1457 | Body_part | denotes | extremities | http://purl.obolibrary.org/obo/UBERON_0002101 |
T5 | 2024-2033 | Body_part | denotes | leukocyte | http://purl.obolibrary.org/obo/CL_0000738 |
GlyCosmos15-MAT
Id | Subject | Object | Predicate | Lexical cue | mat_id |
---|---|---|---|---|---|
T1 | 1159-1163 | Body_part | denotes | bone | http://purl.obolibrary.org/obo/MAT_0000299 |
T2 | 1167-1184 | Body_part | denotes | connective tissue | http://purl.obolibrary.org/obo/MAT_0000301 |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T1 | 0-73 | Sentence | denotes | Serum hyaluronidase aberrations in metabolic and morphogenetic disorders. |
TextSentencer_T2 | 74-188 | Sentence | denotes | Hyaluronidases are endo-glycosidases that degrade both hyaluronan (hyaluronic acid) (HA) and chondroitin sulfates. |
TextSentencer_T3 | 189-326 | Sentence | denotes | Deficiency of hyaluronidase activity has been predicted to result in a phenotype similar to that observed in mucopolysaccharidosis (MPS). |
TextSentencer_T4 | 327-566 | Sentence | denotes | In the present study, we surveyed a variety of patients with phenotypes similar to those observed in MPS, but without significant mucopolysacchariduria to determine if some are based on aberrations in serum hyaluronidase (Hyal-1) activity. |
TextSentencer_T5 | 567-704 | Sentence | denotes | The study included patients with well-characterized dysmorphic disorders occurring on genetic basis, as well as those of unkown etiology. |
TextSentencer_T6 | 705-823 | Sentence | denotes | The purpose of the study was to establish how wide spread were abnormalities in levels of circulating Hyal-1 activity. |
TextSentencer_T7 | 824-930 | Sentence | denotes | A simple and sensitive semi-quantitative zymographic procedure was used for the determination of activity. |
TextSentencer_T8 | 931-1135 | Sentence | denotes | Levels of both beta-N-acetylglucosaminidase and beta-glucuronidase whose activities contribute to the total breakdown of hyaluronan (HA) were also measured, as well as the concentration of circulating HA. |
TextSentencer_T9 | 1136-1349 | Sentence | denotes | Among 48 patients with bone or connective tissue abnormalities, low levels of Hyal-1 activity were found in six patients compared to levels in 100 healthy donors (2.0-3.2 units/microL vs 6(+/- 1 SE) units/microL). |
TextSentencer_T10 | 1350-1652 | Sentence | denotes | These six patients exhibited a wide spectrum of clinical abnormalities, in particular shortened extremities: they included three patients with unknown causes of clinical symptoms, one patient with Sanfilippo disease, one of the seven patients with achondroplasia, and one with hypophosphotemic rickets. |
TextSentencer_T11 | 1653-1861 | Sentence | denotes | Normal levels of serum Hyal-1 activities were found in patients with Morquio disease, GM1 gangliosidosis, I cell-disease, 6 of the 7 patients with achondroplasia, Marfan's-syndrome and Ehlers-Danlos syndrome. |
TextSentencer_T12 | 1862-1910 | Sentence | denotes | No patient totally lacked serum Hyal-1 activity. |
TextSentencer_T13 | 1911-1996 | Sentence | denotes | Serum HA concentration was elevated in patients with Sanfilippo A and I-cell disease. |
TextSentencer_T14 | 1997-2132 | Sentence | denotes | Determination of serum and leukocyte Hyal-1 and serum HA may be useful to evaluate patients with metabolic and morphogenetic disorders. |
TextSentencer_T1 | 0-73 | Sentence | denotes | Serum hyaluronidase aberrations in metabolic and morphogenetic disorders. |
TextSentencer_T2 | 74-188 | Sentence | denotes | Hyaluronidases are endo-glycosidases that degrade both hyaluronan (hyaluronic acid) (HA) and chondroitin sulfates. |
TextSentencer_T3 | 189-326 | Sentence | denotes | Deficiency of hyaluronidase activity has been predicted to result in a phenotype similar to that observed in mucopolysaccharidosis (MPS). |
TextSentencer_T4 | 327-566 | Sentence | denotes | In the present study, we surveyed a variety of patients with phenotypes similar to those observed in MPS, but without significant mucopolysacchariduria to determine if some are based on aberrations in serum hyaluronidase (Hyal-1) activity. |
TextSentencer_T5 | 567-704 | Sentence | denotes | The study included patients with well-characterized dysmorphic disorders occurring on genetic basis, as well as those of unkown etiology. |
TextSentencer_T6 | 705-823 | Sentence | denotes | The purpose of the study was to establish how wide spread were abnormalities in levels of circulating Hyal-1 activity. |
TextSentencer_T7 | 824-930 | Sentence | denotes | A simple and sensitive semi-quantitative zymographic procedure was used for the determination of activity. |
TextSentencer_T8 | 931-1135 | Sentence | denotes | Levels of both beta-N-acetylglucosaminidase and beta-glucuronidase whose activities contribute to the total breakdown of hyaluronan (HA) were also measured, as well as the concentration of circulating HA. |
TextSentencer_T9 | 1136-1349 | Sentence | denotes | Among 48 patients with bone or connective tissue abnormalities, low levels of Hyal-1 activity were found in six patients compared to levels in 100 healthy donors (2.0-3.2 units/microL vs 6(+/- 1 SE) units/microL). |
TextSentencer_T10 | 1350-1652 | Sentence | denotes | These six patients exhibited a wide spectrum of clinical abnormalities, in particular shortened extremities: they included three patients with unknown causes of clinical symptoms, one patient with Sanfilippo disease, one of the seven patients with achondroplasia, and one with hypophosphotemic rickets. |
TextSentencer_T11 | 1653-1861 | Sentence | denotes | Normal levels of serum Hyal-1 activities were found in patients with Morquio disease, GM1 gangliosidosis, I cell-disease, 6 of the 7 patients with achondroplasia, Marfan's-syndrome and Ehlers-Danlos syndrome. |
TextSentencer_T12 | 1862-1910 | Sentence | denotes | No patient totally lacked serum Hyal-1 activity. |
TextSentencer_T13 | 1911-1996 | Sentence | denotes | Serum HA concentration was elevated in patients with Sanfilippo A and I-cell disease. |
TextSentencer_T14 | 1997-2132 | Sentence | denotes | Determination of serum and leukocyte Hyal-1 and serum HA may be useful to evaluate patients with metabolic and morphogenetic disorders. |
T1 | 0-73 | Sentence | denotes | Serum hyaluronidase aberrations in metabolic and morphogenetic disorders. |
T2 | 74-188 | Sentence | denotes | Hyaluronidases are endo-glycosidases that degrade both hyaluronan (hyaluronic acid) (HA) and chondroitin sulfates. |
T3 | 189-326 | Sentence | denotes | Deficiency of hyaluronidase activity has been predicted to result in a phenotype similar to that observed in mucopolysaccharidosis (MPS). |
T4 | 327-566 | Sentence | denotes | In the present study, we surveyed a variety of patients with phenotypes similar to those observed in MPS, but without significant mucopolysacchariduria to determine if some are based on aberrations in serum hyaluronidase (Hyal-1) activity. |
T5 | 567-704 | Sentence | denotes | The study included patients with well-characterized dysmorphic disorders occurring on genetic basis, as well as those of unkown etiology. |
T6 | 705-823 | Sentence | denotes | The purpose of the study was to establish how wide spread were abnormalities in levels of circulating Hyal-1 activity. |
T7 | 824-930 | Sentence | denotes | A simple and sensitive semi-quantitative zymographic procedure was used for the determination of activity. |
T8 | 931-1135 | Sentence | denotes | Levels of both beta-N-acetylglucosaminidase and beta-glucuronidase whose activities contribute to the total breakdown of hyaluronan (HA) were also measured, as well as the concentration of circulating HA. |
T9 | 1136-1349 | Sentence | denotes | Among 48 patients with bone or connective tissue abnormalities, low levels of Hyal-1 activity were found in six patients compared to levels in 100 healthy donors (2.0-3.2 units/microL vs 6(+/- 1 SE) units/microL). |
T10 | 1350-1652 | Sentence | denotes | These six patients exhibited a wide spectrum of clinical abnormalities, in particular shortened extremities: they included three patients with unknown causes of clinical symptoms, one patient with Sanfilippo disease, one of the seven patients with achondroplasia, and one with hypophosphotemic rickets. |
T11 | 1653-1861 | Sentence | denotes | Normal levels of serum Hyal-1 activities were found in patients with Morquio disease, GM1 gangliosidosis, I cell-disease, 6 of the 7 patients with achondroplasia, Marfan's-syndrome and Ehlers-Danlos syndrome. |
T12 | 1862-1910 | Sentence | denotes | No patient totally lacked serum Hyal-1 activity. |
T13 | 1911-1996 | Sentence | denotes | Serum HA concentration was elevated in patients with Sanfilippo A and I-cell disease. |
T14 | 1997-2132 | Sentence | denotes | Determination of serum and leukocyte Hyal-1 and serum HA may be useful to evaluate patients with metabolic and morphogenetic disorders. |
GlyCosmos15-Sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-73 | Sentence | denotes | Serum hyaluronidase aberrations in metabolic and morphogenetic disorders. |
T2 | 74-188 | Sentence | denotes | Hyaluronidases are endo-glycosidases that degrade both hyaluronan (hyaluronic acid) (HA) and chondroitin sulfates. |
T3 | 189-326 | Sentence | denotes | Deficiency of hyaluronidase activity has been predicted to result in a phenotype similar to that observed in mucopolysaccharidosis (MPS). |
T4 | 327-566 | Sentence | denotes | In the present study, we surveyed a variety of patients with phenotypes similar to those observed in MPS, but without significant mucopolysacchariduria to determine if some are based on aberrations in serum hyaluronidase (Hyal-1) activity. |
T5 | 567-704 | Sentence | denotes | The study included patients with well-characterized dysmorphic disorders occurring on genetic basis, as well as those of unkown etiology. |
T6 | 705-823 | Sentence | denotes | The purpose of the study was to establish how wide spread were abnormalities in levels of circulating Hyal-1 activity. |
T7 | 824-930 | Sentence | denotes | A simple and sensitive semi-quantitative zymographic procedure was used for the determination of activity. |
T8 | 931-1135 | Sentence | denotes | Levels of both beta-N-acetylglucosaminidase and beta-glucuronidase whose activities contribute to the total breakdown of hyaluronan (HA) were also measured, as well as the concentration of circulating HA. |
T9 | 1136-1349 | Sentence | denotes | Among 48 patients with bone or connective tissue abnormalities, low levels of Hyal-1 activity were found in six patients compared to levels in 100 healthy donors (2.0-3.2 units/microL vs 6(+/- 1 SE) units/microL). |
T10 | 1350-1652 | Sentence | denotes | These six patients exhibited a wide spectrum of clinical abnormalities, in particular shortened extremities: they included three patients with unknown causes of clinical symptoms, one patient with Sanfilippo disease, one of the seven patients with achondroplasia, and one with hypophosphotemic rickets. |
T11 | 1653-1861 | Sentence | denotes | Normal levels of serum Hyal-1 activities were found in patients with Morquio disease, GM1 gangliosidosis, I cell-disease, 6 of the 7 patients with achondroplasia, Marfan's-syndrome and Ehlers-Danlos syndrome. |
T12 | 1862-1910 | Sentence | denotes | No patient totally lacked serum Hyal-1 activity. |
T13 | 1911-1996 | Sentence | denotes | Serum HA concentration was elevated in patients with Sanfilippo A and I-cell disease. |
T14 | 1997-2132 | Sentence | denotes | Determination of serum and leukocyte Hyal-1 and serum HA may be useful to evaluate patients with metabolic and morphogenetic disorders. |
GlyCosmos15-Glycan
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 167-178 | Glycan | denotes | chondroitin | https://api.glycosmos.org/wurcs2image/latest/png/binary/G43702JT |
T2 | 1739-1742 | Glycan | denotes | GM1 | https://api.glycosmos.org/wurcs2image/latest/png/binary/G48558GR |
GlyCosmos15-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue | glycoepitope_id |
---|---|---|---|---|---|
T1 | 167-178 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | chondroitin | http://www.glycoepitope.jp/epitopes/EP0081 |
T2 | 1739-1742 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | GM1 | http://www.glycoepitope.jp/epitopes/EP0050 |
NCBITAXON
Id | Subject | Object | Predicate | Lexical cue | db_id |
---|---|---|---|---|---|
T1 | 1534-1541 | OrganismTaxon | denotes | patient | 9606 |
T2 | 1865-1872 | OrganismTaxon | denotes | patient | 9606 |
Anatomy-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 1159-1163 | Body_part | denotes | bone | http://purl.obolibrary.org/obo/UBERON_0001474|http://purl.obolibrary.org/obo/UBERON_0002481 |
T3 | 1167-1184 | Body_part | denotes | connective tissue | http://purl.obolibrary.org/obo/UBERON_0002384 |
T4 | 1446-1457 | Body_part | denotes | extremities | http://purl.obolibrary.org/obo/UBERON_0002101 |
T5 | 2024-2033 | Body_part | denotes | leukocyte | http://purl.obolibrary.org/obo/CL_0000738 |
CL-cell
Id | Subject | Object | Predicate | Lexical cue | cl_id |
---|---|---|---|---|---|
T1 | 2024-2033 | Cell | denotes | leukocyte | http://purl.obolibrary.org/obo/CL:0000738 |